Loading...



Shopping cart processing ...
0
Your cart0
Products 0
Price $0.00
Bestsellers Pill categories
Customer Support 24/7
usa canada USA
uk UK
au AU
Live Chat 24/7
Menu
Customer Support 24/7
USA/Canada Toll Free USA
UK UK
AUS AU
Customer Support 24/7
usacanada USA
uk UK
au AU
We accept
  • Visa
  • MasterCard
  • Amex
  • JCB
Currency
USD
Your cart: $0.00 (0 items)
Checkout

Categories list

Choosing us you get:

  • Reliable supplier
  • Low Internet prices
  • Free bonus pills
  • Discount on all future orders
  • Discreet package
  • SSL secure orders
Worldwide Shipping!

Testimonials:

  • Kenny Klunder Chicago, IL, USA
    I am loyal to this shop for more than 3 years. My life time discount makes already 15% and my friends might use it as well. Thank you for accumulation discounts.
More info »

Strattera

Strattera
Strattera is a selective norepinephrine reuptake inhibitor (SNRI) that is used in the treatment of Attention Deficit Hyperactivity Disorder.

Brand: Atomoxetine

Availability: In Stock
Average Delivery Time: 9 Days
Exp. Date: June 2024
View product image
Package Price Per pill Save Order
Strattera 40 mg
180 pills - 40 mg
+ 12 free Viagra 100 mg, 7% discount for future orders
$433.55 $2.41 $250.39 Add to cart
120 pills - 40 mg
+ 8 free Viagra 100 mg, 5% discount for future orders
$295.93 $2.47 $160.03 Add to cart
90 pills - 40 mg
+ 8 free Viagra 100 mg, 5% discount for future orders
$245.91 $2.73 $96.06 Add to cart
60 pills - 40 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$180.93 $3.02 $47.05 Add to cart
30 pills - 40 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$113.99 $3.80 No Add to cart
Strattera 25 mg
270 pills - 25 mg
+ 8 free Viagra 100 mg, 5% discount for future orders
$247.99 $0.92 $129.92 Add to cart
180 pills - 25 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$169.91 $0.94 $82.03 Add to cart
120 pills - 25 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$118.97 $0.99 $48.99 Add to cart
90 pills - 25 mg $92.95 $1.03 $33.02 Add to cart
60 pills - 25 mg $67.93 $1.13 $16.05 Add to cart
30 pills - 25 mg $41.99 $1.40 No Add to cart
Strattera 18 mg
270 pills - 18 mg
+ 8 free Viagra 100 mg, 5% discount for future orders
$265.96 $0.99 $138.95 Add to cart
180 pills - 18 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$182.85 $1.02 $87.09 Add to cart
120 pills - 18 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$127.97 $1.07 $51.99 Add to cart
90 pills - 18 mg $99.91 $1.11 $35.06 Add to cart
60 pills - 18 mg $72.93 $1.22 $17.05 Add to cart
30 pills - 18 mg $44.99 $1.50 No Add to cart
Strattera 10 mg
270 pills - 10 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$156.99 $0.58 $36.47 Add to cart
180 pills - 10 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$107.75 $0.60 $21.22 Add to cart
120 pills - 10 mg $75.29 $0.63 $10.69 Add to cart
90 pills - 10 mg $59.91 $0.67 $4.58 Add to cart
60 pills - 10 mg $42.99 $0.72 No Add to cart

Product description

DRUG TITLE

Strattera (Atomoxetine)

Pharmacological action

Sympathomimetic of central action. Atomoxetine is a highly selective potent inhibitor of presynaptic noradrenaline transporters. Atomoxetine has minimal affinity for other noradrenergic receptors or other neurotransmitter transporters or receptors.


Atomoxetine is not a psychostimulant and is not an amphetamine derivative. No increase in disease symptoms or any adverse events associated with withdrawal syndrome have been reported in clinical trials.


Pharmacokinetics

After oral administration, atomoxetine is rapidly and almost completely absorbed, reaching Cmax in plasma in approximately 1-2 hours. Atomoxetine is well distributed in the body. It has high affinity to plasma proteins, primarily to albumin. Atomoxetine undergoes primary metabolism with the participation of CYP2D6 isoenzyme. The main resulting oxidized metabolite 4-hydroxyatomoxetine is rapidly glucuronized. In pharmacological activity, 4-hydroxyatomoxetine is equivalent to atomoxetine but circulates in the plasma at much lower concentrations. Although 4-hydroxyatomoxetine is primarily formed with CYP2D6, in people with insufficient CYP2D6 activity 4-hydroxyatomoxetine may be formed by some other cytochrome P450 isoenzymes, but more slowly. Atomoxetine does not inhibit or induce the CYP2D6 cycle.


The average T1/2 of atomoxetine after oral administration is 3.6 h in patients with significant metabolism and 21 h in patients with decreased metabolism. Atomoxetine is mainly excreted in the urine as 4-hydroxyatomoxetine-O-glucuronide.

Contraindications to use

Concomitant use with MAO inhibitors, closed-angle glaucoma, hypersensitivity to atomoxetine.


Administration during pregnancy and lactation

Administration during pregnancy and lactation is possible only in case when the expected benefit of therapy for a mother significantly exceeds the potential risk for a fetus or a breast child.


It is unknown whether atomoxetine is excreted with breast milk in humans.


Use in impaired liver function

In patients with moderate hepatic impairment (Child-Pugh class B), the initial and maintenance therapeutic dose should be reduced to 50% of the usual recommended dose. In patients with severe hepatic impairment (Child-Pugh class C), the initial and maintenance therapeutic dose should be reduced to 25% of the usual dose.

Use in renal dysfunction

Atomoxetine may cause arterial hypertension in patients with end-stage chronic renal failure.

Use in children

In clinical studies in children and adolescents, the likelihood of suicidal ideation increased during atomoxetine use. Children and adolescents treated for ADHD require monitoring for aggressive behavior or hostility

Indications for the active substance ATOMOXETIN

Attention deficit hyperactivity disorder (ADHD) in children 6 years and older, adolescents and adults.


Dosage regimen

Taken orally, regardless of meals or with meals, as a single daily dose in the morning. In case of undesirable phenomena when taking the drug once a day, patients may be recommended to take 2 times a day, dividing the dose into a morning dose and a late afternoon or early evening dose.


For children and adolescents with body weight up to 70 kg, the recommended initial daily dose is about 0.5 mg/kg and is increased to a therapeutic daily dose of about 1.2 mg/kg not earlier than after 3 days. If the patient's condition does not improve, the total daily dose may be increased to a maximum dose of 1.8 mg/kg not earlier than 2-4 weeks after the start of treatment. The recommended maintenance dose is approximately 1.2 mg/kg/day. The recommended maximum daily dose is 1.8 mg/kg or 120 mg.


For children and adolescents with body weight over 70 kg and adults, the recommended initial daily dose is 40 mg and is increased to a therapeutic daily dose of about 80 mg not earlier than in 3 days. In case of no improvement of the patient's condition, the total daily dose may be increased to a maximum dose of 120 mg not earlier than 2-4 weeks after the start of treatment. The recommended maintenance dose is 80 mg. The recommended maximum daily dose is 120 mg.


In patients with moderate hepatic impairment (class B on the Child-Pugh scale), the initial and maintenance therapeutic dose should be reduced to 50% of the usual recommended dose. In patients with severe hepatic impairment (Child-Pugh class C), the initial and maintenance therapeutic dose should be reduced to 25% of the usual dose.